| Trial ID: | L5510 |
| Source ID: | NCT02014259
|
| Associated Drug: |
Semaglutide
|
| Title: |
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2|Healthy
|
| Interventions: |
DRUG: semaglutide
|
| Outcome Measures: |
Primary: Area under the semaglutide plasma concentration time curve, From time 0 to 24 hours after the 10th dosing | Secondary: Maximum observed semaglutide plasma concentration, 0 to 24 hours after the 10th dosing|Area under the SNAC (Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate /salcaprozate sodium) plasma concentration time curve, From time 0 to 24 hours after the 10th dosing|Maximum observed SNAC plasma concentration, 0 to 24 hours after the 10th dosing
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
71
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-12-11
|
| Completion Date: |
2014-10-24
|
| Results First Posted: |
|
| Last Update Posted: |
2018-04-19
|
| Locations: |
Novo Nordisk Investigational Site, Hradec Králové, 50005, Czechia|Novo Nordisk Investigational Site, Praha 7, 17000, Czechia|Novo Nordisk Investigational Site, Budapest, 1076, Hungary|Novo Nordisk Investigational Site, Budapest, 1115, Hungary
|
| URL: |
https://clinicaltrials.gov/show/NCT02014259
|
